why choose us

First received: October 26, 2023

Clinical Trial: A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Metastatic Breast Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase Ib/II Trial of Lenvatinib Plus Pembrolizumab Plus Fulvestrant in ER-positive/ HER2- Negative Metastatic Breast Cancer

Brief Summary: The purpose of this study is to test whether the combination of lenvatinib, pembrolizumab, and fulvestrant is a safe and effective treatment that causes few or mild side effects in people with ER+/HER2- metastatic breast cancer.

Read more